Natera (NASDAQ:NTRA) CFO Sells $403,666.55 in Stock

Key Points

• Natera's CFO, Michael Burkes Brophy, sold 2,491 shares of the company's stock for approximately $403,666.55, resulting in a 3.48% decrease in his ownership.
• The company's stock price reached $161.61, with a market cap of $22.18 billion and a negative price-to-earnings ratio of -84.61, following a quarterly earnings report that missed estimates.
• Analysts hold a consensus "Buy" rating for Natera, with target prices ranging from $175.00 to $268.00, indicating optimism despite recent financial challenges.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 2,491 shares of Natera stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the transaction, the chief financial officer directly owned 69,189 shares of the company's stock, valued at approximately $11,212,077.45. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, July 29th, Michael Burkes Brophy sold 3,045 shares of Natera stock. The stock was sold at an average price of $137.40, for a total value of $418,383.00.
• On Monday, July 28th, Michael Burkes Brophy sold 2,019 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $282,276.39.
• On Tuesday, July 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The stock was sold at an average price of $139.58, for a total transaction of $128,413.60.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $139.50, for a total transaction of $105,322.50.
• On Wednesday, July 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The shares were sold at an average price of $141.28, for a total value of $69,933.60.
• On Monday, July 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The stock was sold at an average price of $139.29, for a total value of $83,852.58.

Natera Price Performance

NTRA stock traded up $0.64 during midday trading on Wednesday, reaching $161.61. The company had a trading volume of 1,583,819 shares, compared to its average volume of 1,079,070. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $183.00. The stock has a 50 day moving average price of $160.22 and a 200-day moving average price of $156.35. The company has a market capitalization of $22.18 billion, a price-to-earnings ratio of -84.61 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the firm posted ($0.30) earnings per share. The business's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

A number of institutional investors have recently made changes to their positions in NTRA. Bank of Jackson Hole Trust acquired a new stake in Natera during the 1st quarter worth about $29,000. Rakuten Securities Inc. increased its stake in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares in the last quarter. ORG Partners LLC purchased a new stake in shares of Natera in the first quarter valued at approximately $32,000. TCTC Holdings LLC grew its position in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after acquiring an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its position in Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after acquiring an additional 106 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on NTRA. Wells Fargo & Company assumed coverage on Natera in a research report on Monday, September 22nd. They set an "equal weight" rating and a $175.00 target price for the company. Barclays reaffirmed an "overweight" rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a research note on Friday, August 8th. Cowen reaffirmed a "buy" rating on shares of Natera in a research note on Friday, August 8th. Morgan Stanley reissued an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Finally, Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $192.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.